ACR Applauds Second Round of Medicare Drug Price Negotiations
The ACR applauded the announcement of additional drugs subject to pricing negotiations with the CMS. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare⦠https://t.co/z1LkpWMXqg https://t.co/hqjkqTqJxw
Links:
Jan-31-2025


